Consensus Evolus, Inc.

Stocks

EOLS

US30052C1071

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 21/08/2026 +03			5-day change	1st Jan Change
8.390 ^USD	+0.48%		+2.88%	+26.17%

08-06	Evolus, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	Evolus, Inc. Raises Earnings Guidance for the Full Year 2026	CI

Evolution of the Average Target: Evolus, Inc.

Evolution of the Target Price: Evolus, Inc.

Changes in Analyst Recommendations: Evolus, Inc.

7ccfa9da32aa2ad0e7283d.Fb1gHsXXfnt0nU6JbkcP-YBOcbC4-l7N4lq1sz_Sros.Sv8DJ62gFTY26j3lQyVt1MMpM4LTyG-ouBCYxA-96_xi8hV_oucNT0bKHw~d8aac72d0dec42d015427cb2e5ce46ec

Analysts' recommendations: Evolus, Inc.

11-12	Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025	CI
17/04/25	BTIG Initiates Evolus at Buy With $21 Price Target	MT
08/03/24	Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating	MT
29/01/24	Barclays Upgrades Evolus to Overweight From Equalweight, Raises Price Target to $16 From $10	MT
03/08/23	HC Wainwright Adjusts Price Target on Evolus to $27 From $16, Maintains Buy Rating	MT
07/06/23	Mizuho Securities Adjusts Evolus Price Target to $20 From $17, Maintains Buy Rating	MT
26/05/23	Truist Securities Adjusts Price Target on Evolus to $18 From $14, Maintains Buy Rating	MT
10/05/23	HC Wainwright Adjusts Price Target on Evolus to $16 From $15, Maintains Buy Rating	MT
19/01/23	Mizuho Securities Adjusts Evolus' Price Target to $17 From $15, Keeps Buy Rating	MT
23/06/22	Needham & Co Initiates Coverage on Evolus With Buy Rating, $18 Price Target	MT
12/05/22	Barclays Upgrades Evolus to Equalweight From Underweight, Adjusts Price Target to $10 From $8	MT
20/01/22	Truist Securities Upgrades Evolus to Buy From Hold; Price Target is $11	MT
03/11/21	HC Wainwright Adjusts Evolus' Price Target to $15 From $22, Keeps Buy Rating	MT
13/05/21	Evolus : Barclays Adjusts Evolus' Price Target to $7 From $8, Maintains Underweight Rating	MT
06/05/21	Evolus : Mizuho Securities Upgrades Evolus to Buy From Neutral; Price Target is $15	MT
08/04/21	Evolus : HC Wainwright Adjusts Evolus' Price Target to $22 From $20, Maintains Buy Rating	MT
30/03/21	Evolus : Mizuho Adjusts Evolus' Price Target to $15 From $9, Maintains Neutral Rating	MT
24/03/21	Evolus : HC Wainwright Adjusts Evolus' Price Target to $20 From $18, Maintains Buy Rating	MT
24/02/21	Evolus : Truist Securities Downgrades Evolus to Hold From Buy, Adjusts Price Target to $12 From $6	MT
22/02/21	Evolus : Barclays Adjusts Evolus' Price Target to $8 From $4, Reiterates Underweight Rating	MT
22/02/21	Evolus : Cantor Fitzgerald Adjusts Evolus' Price Target to $20 From $11, Maintains Overweight Rating	MT
22/02/21	Evolus : Mizuho Adjusts Evolus' Price Target to $9 From $5, Maintains Neutral Rating	MT
22/02/21	Evolus : HC Wainwright Adjusts Evolus' Price Target to $18 From $6, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EVOLUS, INC.					+78.78%
	ELI LILLY AND COMPANY					+4.75%
	JOHNSON & JOHNSON					+0.84%
	ABBVIE INC.					+4.39%
	ROCHE HOLDING AG					-1.41%
	NOVARTIS AG					-2.99%
	ASTRAZENECA PLC					+27.25%
	AMGEN INC.					-11.57%
	NOVO NORDISK A/S					+2.95%
	GILEAD SCIENCES, INC.					+7.72%
	Average					+11.07%
	Weighted average by Cap.					+3.38%